-

Thermo Fisher Scientific and Project HOPE Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa

Collaboration designed to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, and Project HOPE, a leading global health and humanitarian organization, today announced a new partnership to improve the wellbeing and treatment outcomes of adolescents and young persons living with HIV in Nigeria, the country with the second largest HIV epidemic worldwide. Nigeria currently accounts for nearly two million individuals living with HIV, contributing to approximately two-thirds of new HIV infections in West and Central Africa.

The partnership greatly advances Project HOPE’s efforts in Northwestern Nigeria by expanding access to critical community HIV testing services. Project HOPE, supported by local community partners, will identify and help connect more HIV positive adolescents and young persons with appropriate treatment and essential social and economic support services, ultimately improving their wellbeing and quality of life. Additionally, Thermo Fisher will engage its employees in volunteer opportunities to augment the services delivered by Project HOPE.

“The theme of this year’s World AIDS Day is “let communities lead,” reminding us to focus on the individuals who are living with this disease and to enable the community partners on the frontline of driving local progress,” said Meron Mathias, vice president, corporate social responsibility, Thermo Fisher Scientific. “This partnership with Project HOPE builds on our meaningful work in the region and allows us to support and learn from a new cohort of essential partners, so they can give more young people living with HIV a greater chance to explore and fulfill their life ambitions.”

Thermo Fisher’s previous support for Project HOPE’s initiatives in countries like Ukraine laid the foundation for the new collaboration to address infectious diseases, particularly HIV/AIDS. This partnership builds on Thermo Fisher’s collaborations with customers, governments and nonprofit organizations to create a more equitable global healthcare environment. For instance, in 2022, the company launched an HIV drug resistance genotyping kit with global heath equity pricing, an offering that’s been adopted by over 30 low- and middle-income countries across Africa, Latin America, the Middle East and Asia; and which has helped drive health policy changes in Kenya.

For over a decade, Project HOPE has been collaborating with public, private, and government partners to improve health in Nigeria. With a focus on HIV/AIDS, Project HOPE strives to support government, local partners, and communities to prevent new infections and enhance health outcomes for the most vulnerable populations in line with the UNAIDS targets toward achieving epidemic control.

“Project HOPE is delighted to collaborate with Thermo Fisher Scientific on this transformative journey to improve the lives of adolescents and young persons in Northwestern Nigeria,” said Dr. Uche RalphOpara, deputy chief health officer, Project HOPE. “Through improved case finding, linkage to care and treatment, and economic strengthening interventions, we aim to empower these young individuals to realize their full potential and lead healthier, more fulfilling lives.”

Thermo Fisher’s commitment to improve health outcomes with customers, patients and communities extends beyond HIV/AIDS. This year, the company launched a pair of breakthrough, FDA-approved blood tests to diagnose preeclampsia—a potentially life-threatening condition that disproportionately impacts pregnant Black women—that were named to TIME’s best inventions of 2023. The company also partnered with Pfizer to expand local access to next-generation-sequencing-based testing for cancer patients in low- and middle-income markets across Africa, Latin America, the Middle East and Asia.

To learn more about Thermo Fisher’s global commitment to health equity, explore the company’s Corporate Social Responsibility Report.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

About Project HOPE

Founded in 1958, Project HOPE is a leading global health and humanitarian organization operating in more than 25 countries around the world. We work side-by-side with local health systems to save lives and improve health. Our mission is at the epicenter of today’s greatest health challenges, including infectious and chronic diseases, disasters and health crises, maternal, neonatal and child health and the policies that impact how health care is delivered. For more information on Project HOPE and its work around the world, visit www.ProjectHOPE.org and follow us on socials @ProjectHOPEorg.

Contacts

Media Contact Information:
Thermo Fisher
Mauricio Minotta
Phone: 760.805.5266
E-mail: mauricio.minotta@thermofisher.com

Project HOPE
Armand Viscarri
Phone: 281.889.8594
Email: AViscarri@projecthope.org

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Thermo Fisher
Mauricio Minotta
Phone: 760.805.5266
E-mail: mauricio.minotta@thermofisher.com

Project HOPE
Armand Viscarri
Phone: 281.889.8594
Email: AViscarri@projecthope.org

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom